Figure 4 | Scientific Reports

Figure 4

From: PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Figure 4

Quantitative measurement of gene silencing for MDR1 and BCL2 on MDR ovarian cancer cells treated with siRNA@PLGA NPs. (A) The mRNA levels of MDR1 and BCL2 were determined by qRT-PCR method 24 h after SKOV3-TR and A2780-CP20 cells were treated with PLGA NPs containing MDR1 and BCL2 siRNA. (B) The expression levels of P-glycoproteins and BCL2 proteins were measured by immunoblotting method 24 h after SKOV3-TR and A2780-CP20 cells were treated with siRNA@PLGA NPs. In the figure are reported the cropped gels/blots obtained by each protein evaluation. All gels were run in the same experimental conditions and a representative immunoblotting image was presented. The levels of P-glycoproteins or BCL2 proteins were quantitatively plotted relative to those of mock sample cells. All results are represented as the mean ± s.d. (n = 3).

Back to article page